Format

Send to

Choose Destination
J Thorac Cardiovasc Surg. 2015 May;149(5):1374-81. doi: 10.1016/j.jtcvs.2014.10.128. Epub 2015 Feb 7.

Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma.

Author information

1
Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass. Electronic address: ebaldini@partners.org.
2
Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
3
Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.
4
Division of Thoracic Surgery, Geisinger Health System, Wilkes-Barre, Pa.
5
University of Kentucky College of Medicine, Lexington, Ky.
6
Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass.
7
Division of Thoracic Surgery, Debakey Institute, Houston, Tex.

Abstract

OBJECTIVE:

We have previously described patterns of failure after extrapleural pneumonectomy and multimodality therapy for malignant pleural mesothelioma and sought to update our results with a larger cohort of recent patients.

METHODS:

A total of 169 patients underwent extrapleural pneumonectomy without preoperative chemotherapy between 2001 and 2010. Data for treatment, recurrence, and survival were determined from medical records. A thoracic radiologist reviewed postoperative computed tomography or positron emission tomography computed tomography scans to determine sites of recurrence. Time to recurrence was estimated by the Kaplan-Meier method. Rates were compared using the Fisher exact test.

RESULTS:

The median age of patients was 62 years. Histology on final pathology was epithelial for 104 patients (62%) and nonepithelial for 65 patients (38%). A total of 132 patients (78%) received heated intraoperative chemotherapy; 77 patients (45%) received adjuvant chemotherapy, and 71 patients (42%) received adjuvant radiation therapy. Most chemotherapy regimens included platinum or pemetrexed. Median radiation therapy dose was 54 Gy. Among 158 evaluable patients, a recurrence developed in 118 (75%). Median follow-up was 83 months, median time to recurrence was 13.1 months, and median survival was 15 months. Sites of first recurrence were in the ipsilateral hemithorax or mediastinum for 54% of patients, in the abdomen for 39% of patients, in the contralateral hemithorax for 28% of patients, and in other distant sites for 5% of patients. Some patients had simultaneous recurrences in multiple sites.

CONCLUSIONS:

The most common site of recurrence after extrapleural pneumonectomy and planned multimodality therapy remains the ipsilateral hemithorax (including mediastinum), and true distant failure (other than the abdomen or contralateral hemithorax) remains unusual. The distribution of recurrences is strikingly similar to our prior report.

PMID:
25772281
PMCID:
PMC6042876
DOI:
10.1016/j.jtcvs.2014.10.128
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center